Peptinov

Focus: Peptinov is a French biotechnology company specializing in peptide-based active immunotherapy, currently in early-stage clinical development with a focused pipeline in osteoarthritis.

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Peptinov

AI assessmentNot Hiring

No open roles listed right now. Follow Peptinov to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

PPV-06 10 μg

Knee Osteoarthritis

Phase 1

Clinical Trials (1)

NCT04447898Dose Escalation Study Assessing the Safety and Immune Response of PPV-06 Vaccine

Phase 1

Help build intelligence for Peptinov

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage biotech with specialized peptide immunotherapy focus offers opportunity to shape company trajectory from clinical stage
Opportunity to work on differentiated modality (peptide-based active immunotherapy) in high-prevalence indication (knee osteoarthritis)
Located in Paris, Europe's growing biotech hub, with potential regulatory advantages via EMA pathway

Watch Out For

Currently zero active job openings suggests company is not in hiring phase, indicating potential cash constraints or early maturity
Only 2 active clinical trials with no Phase 3 programs represents very early pipeline with extended timeline to meaningful value creation
Limited public information on funding, financials, employee count, and company stage creates visibility gaps for due diligence

Generated by Claude from Peptinov's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PPV-06

Osteoarthritis, Knee

Phase 2

Clinical Trials (1)

NCT06605963PPV-06 Vaccine in Inflammatory Knee Osteoarthritis

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo